|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Genetic association of interleukin-6 polymorphism (-174 G/C) with chronic liver diseases and hepatocellular carcinoma显示文摘Interleukin-6 (IL-6) is a pleiotropic cytokine which is expressed in many inflammatory cells in response to different types of stimuli, regulating a number of biological processes. The IL-6 gene is polymorphic in both the 5' and 3' flanking regions and more than 150 single nucleotide polymorphisms have been identified so far. Genetic polymorphisms of IL-6 may affect the outcomes of several diseases, where the presence of high levels of circulating IL-6 have been correlated to the stage and/or the progression of the disease itself. The -174 G/C polymorphism is a frequent polymorphism, that is located in the upstream regulatory region of the IL-6 gene and affects IL-6 production. However, the data in the literature on the genetic association between the -174 G/C polymorphism and some specific liver diseases characterized by different etiologies are still controversial. In particular, most of the studies are quite unanimous in describing a correlation between the presence of the high-producer genotype and a worse evolution of the chronic liver disease. This is valid for patients with hepatitis C virus (HCV)-related chronic hepatitis and liver cirrhosis and hepatocellu-lar carcinoma (HCC) whatever the etiology. Studies in hepatitis B virus-related chronic liver diseases are not conclusive, while specific populations like non alcoholic fatty liver disease/non-alcoholic steatohepatitis, autoimmune and human immunodeficiency virus/HCV coinfected patients show a higher prevalence of the lowproducer genotype, probably due to the complexity of these clinical pictures. In this direction, a systematic revision of these data should shed more light on the role of this polymorphism in chronic liver diseases and HCC. | Lydia Giannitrapani Maurizio Soresi Daniele Balasus Anna Licata Giuseppe Montalto | 2013 | World Journal of Gastroenterology2013，19，16： | 19 |
| 2 | Non invasive tools for the diagnosis of liver cirrhosis显示文摘Liver cirrhosis(LC),the end stage of many forms of chronic hepatitis of different etiologies is a diffuse process characterized by fibrosis and the conversion of normal liver architecture into structurally abnormal nodules surrounded by annular fibrosis.This chronic progressive clinical condition,leads to liver cell failure and portal hypertension,which can favour the onset of hepatocellular carcinoma.Defining the phase of the natural history is crucial for therapeutic choice and prognosis.Liver biopsy is currently considered the best available standard of reference but it has some limits,so alternative tools have been developed to substitute liver biopsy when assessing liver fibrosis.Serum markers offer a cost-effective alternative to liver biopsy being less invasive and theoretically without complications.They can be classified into direct and indirect markers which may be used alone or in combination to produce composite scores.Diagnostic imaging includes a number of instruments and techniques to estimate liver fibrosis and cirrhosis like ultrasound(US),US Doppler,contrast enhanced US andElastography.US could be used for the diagnosis of advanced LC while is not able to evaluate progression of fibrosis,in this case Elastography is more reliable.This review aims to revise the most recent data from the literature about non invasive methods useful in defining liver fibrosis. | Maurizio Soresi Lydia Giannitrapani Melchiorre Cervello Anna Licata Giuseppe Montalto | 2014 | World Journal of Gastroenterology2014，20，48： | 15 |
| 3 | Hyperferritinemia is a risk factor for steatosis in chronic liver disease显示文摘AIM: To investigate the relationship between ferritin and steatosis in patients with chronically abnormal liver function tests (LFTs) and high ferritin level. METHODS: One hundred and twenty-four consecutive patients with hyperferritinemia (male > 300 ng/mL, female > 200 ng/mL) were evaluated; clinical, biochemical and serological data, iron status parameters, HFE gene mutations and homeostasis model assessment score were obtained. Steatosis was graded by ultrasound as absent or present. Histology was available in 53 patients only. RESULTS: Mean level of ferritin was 881 ± 77 ng/mL in men and 549 ± 82 ng/mL in women. The diagnosis was chronic hepatitis C in 53 (42.7%), non-alcoholic fatty liver disease/non-alcoholic steatohepatitis in 57 (45.9%), and cryptogenic liver damage in 14 (11.3%). None was diagnosed as hereditary hemochromatosis (HH). Hepatic siderosis on liver biopsy was present in 17 of 54 (32%) patients; grade 1 in eight and grade 2 in nine. Overall, 92 patients (74.2%) had steatosis. By logistic regression, ferritin and γ-glutamyltransferase were independent predictors of steatosis. Ferritin levels were signifi cantly related to low platelet count, steatosis and hepatitis C virus infection. CONCLUSION: In a non-obese cohort of non-alcoholic patients with chronically abnormal LFTs without HH, high serum ferritin level is a risk factor for steatosis. | Anna Licata Maria Elena Nebbia Giuseppe Cabibbo Giovanna Lo Iacono Francesco Barbaria Virna Brucato Nicola Alessi Salvatore Porrovecchio Vito Di Marco Antonio Craxì Calogero Cammà | 2009 | World Journal of Gastroenterology2009，15，17： | 6 |
| 4 | clinical course and prognostic factors of hepatorenal syndrome:a retrospective single-center cohort study显示文摘AIM: To investigate clinical and biochemical features of hepatorenal syndrome(HRS), to assess short and long- term survival evaluating potential predictors of early mortality. METHODS: Sixty-two patients with liver cirrhosis and renal failure, defined as a serum creatinine value > 1.5 mg/dL on at least two measurements within 48 h, admitted to our tertiary referral Unit from 2001 to 201, were retrospectively reviewed. Among them, 33 patients(53.2%) fulfilled the revised criteria of the International Ascites Club for the diagnosis of HRS. Twenty-eight patients were treated with combinations of terlipressin and albumin, two with dopamine and al- bumin, and three with albumin alone. No patients were suitable for liver transplantation. Complete response was defined as normalization of creatinine levels to less than 1.5 mg/dL, partial response as a decrease of at least 50% but not to less than 1.5 mg/dL, no response as no reduction in creatinine or a decrease of less 50% compared to pre-treatment values. All of the patients were followed up for at least 1 year until January 2013. RESULTS: HRS type 1 was diagnosed in 15 patients(45.5%). Hepatitis C virus infection was the primary etiology(69.6%), followed by alcohol(15.2%), and cryptogenesis(15.2%). Complete response to therapy was obtained in only 3 cases(9.1%) and partial re- sponse in 7 patients(21.2%). Median survival was 30 d(range: 10-274) without significant differences be- tween type 1 and type 2 HRS. By univariate analysis, Child-Pugh class C(P = 0.009), presence of hepatocel- lular carcinoma(P = 0.04), low serum sodium(P = 0.02), high bilirubin values(P = 0.009) and high Model for End-stage Liver Disease(MELD) score(P = 0.03) were predictive factors of 30-d mortality. By multivari- ate analysis, only serum sodium < 132 mEq/L(OR = 31.39; P = 0.02) and MELD score > 27(OR = 18.72; P = 0.01) were independently associated with a survival of less than one month. CONCLUSION: HRS still has a poor prognosis, even when vasoactive drug therapies are extensively used. | Anna Licata Marcello Maida Ambra Bonaccorso Fabio Salvatore Macaluso Maria Cappello Antonio Craxì Piero Luigi Almasio | 2013 | World Journal of Hepatology2013，5，12： | 2 |
| 5 | IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease显示文摘 | Salvatore Petta Stefania Grimaudo Calogero Cammà Daniela Cabibi Vito Di Marco Giusalba Licata Rosaria Maria Pipitone Antonio Craxì | 2012 | Journal of Hepatology2012，，6： | 2 |
| 6 | Measurement of the integrated luminosity of the Phase 2 data of the Belle Ⅱ experiment显示文摘From April to July 2018,a data sample at the peak energy of the T(4 S) resonance was collected with the Belle Ⅱ detector at the SuperKEKB electron-positron collider.This is the first data sample of the Belle Ⅱ experiment.Using Bhabha and digamma events,we measure the integrated luminosity of the data sample to be(496.3±0.3±3.0) pb-1,where the first uncertainty is statistical and the second is systematic.This work provides a basis for future luminosity measurements at Belle Ⅱ. | F.Abudinén I.Adachi P.Ahlburg H.Aihara N.Akopov A.Aloisio F.Ameli L.Andricek N.Anh Ky D.M.Asner H.Atmacan T.Aushev V.Aushev T.Aziz K.Azmi V.Babu S.Baehr S.Bahinipati A.M.Bakich P.Bambade Sw.Banerjee S.Bansal V.Bansal M.Barrett J.Baudot A.Beaulieu J.Becker P.K.Behera J.V.Bennett E.Bernieri F.U.Bernlochner M.Bertemes M.Bessner S.Bettarini V.Bhardwaj F.Bianchi T.Bilka S.Bilokin D.Biswas G.Bonvicini A.Bozek M.Bračko P.Branchini N.Braun T.E.Browder A.Budano S.Bussino M.Campajola L.Cao G.Casarosa C.Cecchi D.Červenkov M.-C.Chang P.Chang R.Cheaib V.Chekelian Y.Q.Chen Y.-T.Chen B.G.Cheon K.Chilikin H.-E.Cho K.Cho S.Cho S.-K.Choi S.Choudhury D.Cinabro L.Corona L.M.Cremaldi S.Cunliffe T.Czank F.Dattola E.De La Cruz-Burelo G.De Nardo M.De Nuccio G.De Pietro R.de Sangro M.Destefanis S.Dey A.De Yta-Hernandez F.Di Capua S.Di Carlo J.Dingfelder Z.Doležal I.Domínguez Jiménez T.V.Dong K.Dort S.Dubey S.Duell S.Eidelman M.Eliachevitch T.Ferber D.Ferlewicz G.Finocchiaro S.Fiore A.Fodor F.Forti A.Frey B.G.Fulsom M.Gabriel E.Ganiev M.Garcia-Hernandez R.Garg A.Garmash V.Gaur A.Gaz U.Gebauer A.Gellrich J.Gemmler T.Geßler R.Giordano A.Giri B.Gobbo R.Godang P.Goldenzweig B.Golob P.Gomis P.Grace W.Gradl E.Graziani D.Greenwald C.Hadjivasiliou S.Halder K.Hara T.Hara O.Hartbrich K.Hayasaka H.Hayashii C.Hearty M.T.Hedges I.Heredia de la Cruz M.Hernández Villanueva A.Hershenhorn T.Higuchi E.C.Hill H.Hirata M.Hoek S.Hollitt T.Hotta C.-L.Hsu Y.Hu K.Huang T.Iijima K.Inami G.Inguglia J.Irakkathil Jabbar A.Ishikawa R.Itoh M.Iwasaki Y.Iwasaki S.Iwata P.Jackson W.W.Jacobs D.E.Jaffe E.-J.Jang H.B.Jeon S.Jia Y.Jin C.Joo J.Kahn H.Kakuno A.B.Kaliyar G.Karyan Y.Kato T.Kawasaki H.Kichimi C.Kiesling B.H.Kim C.-H.Kim D.Y.Kim S.-H.Kim Y.K.Kim Y.Kim T.D.Kimmel K.Kinoshita C.Kleinwort B.Knysh P.Kodyš T.Koga I.Komarov T.Konno S.Korpar D.Kotchetkov N.Kovalchuk T.M.G.Kraetzschmar P.Križan R.Kroeger J.F.Krohn P.Krokovny W.Kuehn T.Kuhr M.Kumar R.Kumar K.Kumara S.Kurz A.Kuzmin Y.-J.Kwon S.Lacaprara Y.-T.Lai C.La Licata K.Lalwani L.Lanceri J.S.Lange K.Lautenbach I.-S.Lee S.C.Lee P.Leitl D.Levit P.M.Lewis C.Li L.K.Li S.X.Li Y.M.Li Y.B.Li J.Libby K.Lieret L.Li Gioi J.Lin Z.Liptak Q.Y.Liu D.Liventsev S.Longo A.Loos F.Luetticke T.Luo C.MacQueen Y.Maeda M.Maggiora S.Maity E.Manoni S.Marcello C.Marinas A.Martini M.Masuda K.Matsuoka D.Matvienko J.McNeil J.C.Mei F.Meier M.Merola F.Metzner M.Milesi C.Miller K.Miyabayashi H.Miyata R.Mizuk G.B.Mohanty H.Moon T.Morii H.-G.Moser F.Mueller F.J.Müller Th.Muller R.Mussa K.R.Nakamura E.Nakano M.Nakao H.Nakayama H.Nakazawa M.Nayak G.Nazaryan D.Neverov M.Niiyama N.K.Nisar S.Nishida K.Nishimura M.Nishimura M.H.A.Nouxman B.Oberhof S.Ogawa Y.Onishchuk H.Ono Y.Onuki P.Oskin H.Ozaki P.Pakhlov G.Pakhlova A.Paladino T.Pang E.Paoloni H.Park S.-H.Park B.Paschen A.Passeri S.Patra S.Paul T.K.Pedlar I.Peruzzi R.Peschke R.Pestotnik M.Piccolo L.E.Piilonen P.L.M.Podesta-Lerma V.Popov C.Praz E.Prencipe M.T.Prim M.V.Purohit P.Rados M.Remnev P.K.Resmi I.Ripp-Baudot M.Ritter M.Ritzert G.Rizzo L.B.Rizzuto S.H.Robertson D.Rodríguez Pérez J.M.Roney C.Rosenfeld A.Rostomyan N.Rout G.Russo D.Sahoo Y.Sakai D.A.Sanders S.Sandilya A.Sangal L.Santelj P.Sartori Y.Sato V.Savinov B.Scavino M.Schram H.Schreeck J.Schueler C.Schwanda A.J.Schwartz B.Schwenker R.M.Seddon Y.Seino A.Selce K.Senyo M.E.Sevior C.Sfienti C.P.Shen H.Shibuya J.-G.Shiu A.Sibidanov F.Simon S.Skambraks R.J.Sobie A.Soffer A.Sokolov E.Solovieva S.Spataro B.Spruck M.Starič S.Stefkova Z.S.Stottler R.Stroili J.Strube M.Sumihama T.Sumiyoshi D.J.Summers W.Sutcliffe M.Tabata M.Takizawa U.Tamponi S.Tanaka K.Tanida H.Tanigawa N.Taniguchi Y.Tao P.Taras F.Tenchini E.Torassa K.Trabelsi T.Tsuboyama N.Tsuzuki M.Uchida I.Ueda S.Uehara T.Uglov K.Unger Y.Unno S.Uno P.Urquijo Y.Ushiroda S.E.Vahsen R.van Tonder G.S.Varner K.E.Varvell A.Vinokurova L.Vitale A.Vossen E.Waheed H.M.Wakeling K.Wan W.Wan Abdullah B.Wang M.-Z.Wang X.L.Wang A.Warburton M.Watanabe S.Watanuki J.Webb S.Wehle N.Wermes C.Wessel J.Wiechczynski P.Wieduwilt H.Windel E.Won S.Yamada W.Yan S.B.Yang H.Ye J.Yelton J.H.Yin M.Yonenaga Y.M.Yook C.Z.Yuan Y.Yusa L.Zani J.Z.Zhang Z.Zhang V.Zhilich Q.D.Zhou X.Y.Zhou V.I.Zhukova V.Zhulanov A.Zupanc | 2020 | Chinese Physics C2020，44，2： | 2 |
| 7 | The future etourism intermedi-aries显示文摘 | BUHALISA D LICATA M C | 2002 | Tourism Management2002，23，3： | 1 |
| 8 | Analysis of TCR Vbeta repertoire and cytokine gene expression in patients with idiopathic dilated cardiomyopathy显示文摘 | LUPPI P LICATA A HALUSZCZAK C | 2001 | J Autoimmun2001，16，1： | 1 |
| 9 | Bleeding cerebral neoplasms with symptomatichematoma显示文摘 | Licata B Turazzi S | 2003 | J Neurosurg Sci2003，47，： | 1 |
| 10 | Effects of high-dose furosemide and small volume hypertonie saline solution infusion in comparison with a high-dose furosemide as bolus in refractory congestive heart failure:long term effects 显示文摘 | Licata G | 2003 | Am Heart J2003，145，： | 1 |
| 11 | Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosenmide as bolus in refractory congestive heart failure:Long-term effects显示文摘 | Licata G Di Pasquale P Parrinello G | 2003 | Am Heart J2003，145，3： | 1 |
| 12 | Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: Long-term effects显示文摘 | Giuseppe Licata Pietro Di Pasquale Gaspare Parrinello Antonietta Cardinale Angela Scandurra Giuseppe Follone Christiano Argano Antonino Tuttolomondo Salvatore Paterna | 2003 | American Heart Journal2003，，3： | 1 |
| 13 | Timing is everything: order of administration of 5-aza 2' deoxycytidine, trichostatin A and tamoxifen changes estrogen receptor mRNA expression and cell sensitivity显示文摘 | Hostetter CL Licata LA Keen JC | 2009 | Cancer Lett2009，275，2： | 1 |
| 14 | Comparison of efficacies of levofoxacin andoral coiprofloxacin in a rabbit model of a staphylo- coccal abscess显示文摘 | Femand J Barrett JF Licata L | 1999 | Antimicro Agents Chemother1999，43，： | 1 |
| 15 | Inorganic anions in goat and ovine milk from Calabria by suppressed ion chromatography显示文摘 | Licata P Naccari F Bella Di G | | 0，，： | 1 |
| 16 | Reference Pricing Studies in Mar- keting:A Synthesis of Research Results显示文摘 | Biswas A Wilson E J Licata JW | 1993 | Journal of Business Re- search1993，27，3： | 1 |
| 17 | Exercise and pharmacological countermeasures for bone loss during long duration space flight显示文摘 | Cavanagh PR Licata AA Rice AJ | 2005 | Gravit Space Biol Bull2005，18，2： | 1 |
| 18 | Post traumatichy drocephalus显示文摘 | Licata C Cristofoii L Gambin R | 2001 | Neurosurg Sci2001，45，3： | 1 |
| 19 | Isomers of alpha - tocopheryl acetate and their biological activity显示文摘 | STANLEY R LICATA S B | 1982 | Lipids1982，6，5： | 1 |
| 20 | Heavy metals in liver and muscle of bluefin tuna (Thunnus thynnus) caught in the straits of Messina(Sicily, Italy)显示文摘 | Licata P Trombetta D Cristani M | 2005 | Environ Monit Assess2005，107，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员